Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
- 20 October 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (30) , 3570-3580
Abstract
PURPOSE: In patients with lung cancer, dyspnea is one of the most prevalent and disabling symptoms, for which effective treatments are lacking. We examined the efficacy of a nurse-led brief behavioral intervention to improve dyspnea in patients with advanced lung cancer. METHODS: Patients with advanced lung cancer reporting at least moderate breathlessness (n = 247) were enrolled in a randomized trial of a nurse-led two-session intervention (focused on breathing techniques, postural positions, and fan therapy) versus usual care. At baseline and weeks 8 (primary end point), 16, and 24, participants completed measures of dyspnea (Modified Medical Research Council Dyspnea Scale [mMRCDS]; Cancer Dyspnoea Scale [CDS]), quality of life (Functional Assessment of Cancer Therapy-Lung [FACT-L]), psychological symptoms (Hospital Anxiety and Depression Scale), and activity level (Godin-Shephard Leisure Time Physical Activity Questionnaire). To examine intervention effects, we conducted analysis of covariance and longitudinal mixed effects models. RESULTS: The sample (Age mean = 66.15 years; 55.9% female) primarily included patients with advanced non–small cell lung cancer (85.4%). Compared with usual care, the intervention improved the primary outcome of patient-reported dyspnea on the mMRCDS (difference = –0.33 [95% CI, –0.61 to –0.05]) but not the CDS total score at 8 weeks. Intervention patients also reported less dyspnea on the CDS sense of discomfort subscale (difference = –0.59 [95% CI, –1.16 to –0.01]) and better functional well-being per the FACT-L (difference = 1.39 [95% CI, 0.18 to 2.59]) versus the control group. Study groups did not differ in overall quality of life, psychological symptoms, or activity level at 8 weeks or longitudinally over 24 weeks. CONCLUSION: For patients with advanced lung cancer, a scalable behavioral intervention alleviated the intractable symptom of dyspnea. Further research is needed on ways to enhance intervention effects over the long-term and across additional outcomes.Keywords
This publication has 58 references indexed in Scilit:
- Current Management Options for Dyspnea in Cancer PatientsCurrent Treatment Options in Oncology, 2023
- Pharmacologic Interventions for Breathlessness in Patients With Advanced CancerJAMA Network Open, 2021
- Nonpharmacological Interventions for Managing Breathlessness in Patients With Advanced CancerJAMA Oncology, 2021
- High-Flow Oxygen and High-Flow Air for Dyspnea in Hospitalized Patients with Cancer: A Pilot Crossover Randomized Clinical TrialThe Oncologist, 2020
- What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancerSupportive Care in Cancer, 2015
- Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancerCancer Medicine, 2015
- The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional studySupportive Care in Cancer, 2013
- Dyspnea experience in patients with lung cancer in palliative careEuropean Journal of Oncology Nursing, 2008
- Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrumentLung Cancer, 1995
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987